Leading Research to Understand, Treat, and Prevent Infectious, Immunologic, and Allergic Diseases
Visit us on the Web
Researchers Launch Phase 1 Trial of Potential MRSA Treatment
NIAID-funded researchers have launched a Phase 1 clinical trial of the candidate oral antibiotic EDP-788, a drug intended to treat methicillin-resistant Staphylococcus aureus (MRSA) infections. The trial, conducted by biotechnology company Enanta Pharmaceuticals through a contract with NIAID, will evaluate the drug’s safety and how it is broken down and processed in the body.
For more information on EDP-788, MRSA, and the new clinical trial, see the NIAID media availability at: http://www.niaid.nih.gov/